Acadia Pharmaceuticals Announces USPTO Issued Notice Of Allowance For U.S. Patent Application No. 17/590,496, Titled “Methods and Compositions for Treatment of Rett Syndrome.”

Acadia Pharmaceuticals has received a Notice of Allowance from the USPTO for its U.S. Patent Application No. 17/590,496, which pertains to methods and compositions for treating Rett Syndrome. This patent extends the company's protections for its drug, trofinetide, until March 2041, allowing for weight-banded dosing. The announcement may have implications for the company's market position and future revenue potential.